Danske Bank A S increased its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 34.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,610,467 shares of the company’s stock after buying an additional 411,200 shares during the quarter. Danske Bank A S’s holdings in Kenvue were worth $28,441,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP lifted its holdings in shares of Kenvue by 3.0% in the 3rd quarter. Allworth Financial LP now owns 39,459 shares of the company’s stock valued at $754,000 after buying an additional 1,152 shares during the period. Eurizon Capital SGR S.p.A. increased its holdings in Kenvue by 272.7% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 867,187 shares of the company’s stock worth $15,316,000 after acquiring an additional 634,493 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of Kenvue by 16.3% during the 3rd quarter. Maryland State Retirement & Pension System now owns 115,925 shares of the company’s stock worth $2,047,000 after purchasing an additional 16,259 shares during the last quarter. First Command Advisory Services Inc. lifted its position in shares of Kenvue by 238.6% in the third quarter. First Command Advisory Services Inc. now owns 8,767 shares of the company’s stock valued at $157,000 after acquiring an additional 6,178 shares in the last quarter. Finally, New York Life Investment Management LLC lifted its holdings in Kenvue by 2.4% in the 3rd quarter. New York Life Investment Management LLC now owns 702,125 shares of the company’s stock valued at $12,400,000 after purchasing an additional 16,254 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Kenvue Stock Performance
Shares of KVUE opened at $19.31 on Tuesday. Kenvue Inc. has a twelve month low of $14.06 and a twelve month high of $20.13. The firm has a market capitalization of $37.09 billion, a P/E ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The firm’s 50-day moving average is $18.46 and its two-hundred day moving average is $18.29. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. Kenvue’s revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.28 earnings per share. On average, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is 95.45%.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the company. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. UBS Group upped their price objective on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. Barclays lifted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Finally, HSBC reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Ten analysts have rated the stock with a Hold rating. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.29.
Get Our Latest Report on Kenvue
Kenvue Company Profile
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
See Also
- Five stocks we like better than Kenvue
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
